Cost-Effectiveness of drug compliance in type 2 diabetes mellitus patients

Autores
Maciel, Olga; Vera, Zully; Marin, Gustavo Horacio; Maidana, Mabel; Samaniego, Lourdes; Lugo, Gladys; Mastroianni, Patricia
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Type 2 diabetes mellitus affects 15% of the population around the world, causing health complications and increasing the treatment’s costs. Being a chronic outpatient treatment disease, patient compliance is higher importance to achieve therapeutic success. The present study measure the cost effectiveness of the compliance of this disease. An observational, cross-sectional, pharmaco-economic study was performed. A National program to stimulate treatment adherence was taken as intervention stage. Compliance was measure by Morisky-Green test and details of the events in each patient's health (medication, consultations, hospitalization and concomitant treatments) were used to determinate the direct costs for Ministry of Public Health. Effectiveness was measured by percentage of glycated hemoglobin (HbA1c). The sample obtained was 55 patients, which were grouped into 31 compliant and 24 non-compliant. The costeffectiveness of compliance was 466 US$ / compliant effective patient and 1,807 US$ / non-compliant effective patient. The cost-effectiveness of hypoglycemic drug therapy compliance is significantly lower (almost 4 times) than non-compliance. Type 2 Diabetes Mellitus patients that have no therapy adherence are not able to maintain protective levels of HbA1c. In addition, for the Ministry of Public Health, the lack of adherence requires more budget to accomplished the health goals.
Fil: Maciel, Olga. Universidad Nacional de Asunción; Paraguay
Fil: Vera, Zully. Universidad Nacional de Asunción; Paraguay
Fil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; Argentina
Fil: Maidana, Mabel. Universidad Nacional de Asunción; Paraguay
Fil: Samaniego, Lourdes. Universidad Nacional de Asunción; Paraguay
Fil: Lugo, Gladys. Universidad Nacional de Asunción; Paraguay
Fil: Mastroianni, Patricia. Universidade Estadual Paulista Julio de Mesquita Filho; Brasil
Materia
Cost-effectiveness
Type 2 Diabetes
Adherence
Pharmacotherapy compliance
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/84321
Acceder
id CONICETDig_1c57a4c90b3298cf764bf10a13bc5a33
oai_identifier_str oai:ri.conicet.gov.ar:11336/84321
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Cost-Effectiveness of drug compliance in type 2 diabetes mellitus patientsMaciel, OlgaVera, ZullyMarin, Gustavo HoracioMaidana, MabelSamaniego, LourdesLugo, GladysMastroianni, PatriciaCost-effectivenessType 2 DiabetesAdherencePharmacotherapy compliancehttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Type 2 diabetes mellitus affects 15% of the population around the world, causing health complications and increasing the treatment’s costs. Being a chronic outpatient treatment disease, patient compliance is higher importance to achieve therapeutic success. The present study measure the cost effectiveness of the compliance of this disease. An observational, cross-sectional, pharmaco-economic study was performed. A National program to stimulate treatment adherence was taken as intervention stage. Compliance was measure by Morisky-Green test and details of the events in each patient's health (medication, consultations, hospitalization and concomitant treatments) were used to determinate the direct costs for Ministry of Public Health. Effectiveness was measured by percentage of glycated hemoglobin (HbA1c). The sample obtained was 55 patients, which were grouped into 31 compliant and 24 non-compliant. The costeffectiveness of compliance was 466 US$ / compliant effective patient and 1,807 US$ / non-compliant effective patient. The cost-effectiveness of hypoglycemic drug therapy compliance is significantly lower (almost 4 times) than non-compliance. Type 2 Diabetes Mellitus patients that have no therapy adherence are not able to maintain protective levels of HbA1c. In addition, for the Ministry of Public Health, the lack of adherence requires more budget to accomplished the health goals.Fil: Maciel, Olga. Universidad Nacional de Asunción; ParaguayFil: Vera, Zully. Universidad Nacional de Asunción; ParaguayFil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; ArgentinaFil: Maidana, Mabel. Universidad Nacional de Asunción; ParaguayFil: Samaniego, Lourdes. Universidad Nacional de Asunción; ParaguayFil: Lugo, Gladys. Universidad Nacional de Asunción; ParaguayFil: Mastroianni, Patricia. Universidade Estadual Paulista Julio de Mesquita Filho; BrasilB. M. Vrushabendra Swamy2018-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/84321Maciel, Olga; Vera, Zully; Marin, Gustavo Horacio; Maidana, Mabel; Samaniego, Lourdes; et al.; Cost-Effectiveness of drug compliance in type 2 diabetes mellitus patients; B. M. Vrushabendra Swamy; Research Journal of Pharmaceutical, Biological and Chemical Sciences; 9; 5; 10-2018; 1824-18290975-8585CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.rjpbcs.com/2018_9.5.htmlinfo:eu-repo/semantics/altIdentifier/url/https://www.rjpbcs.com/pdf/2018_9(5)/[230].pdfinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:18:58Zoai:ri.conicet.gov.ar:11336/84321instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:18:58.907CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Cost-Effectiveness of drug compliance in type 2 diabetes mellitus patients
title Cost-Effectiveness of drug compliance in type 2 diabetes mellitus patients
spellingShingle Cost-Effectiveness of drug compliance in type 2 diabetes mellitus patients
Maciel, Olga
Cost-effectiveness
Type 2 Diabetes
Adherence
Pharmacotherapy compliance
title_short Cost-Effectiveness of drug compliance in type 2 diabetes mellitus patients
title_full Cost-Effectiveness of drug compliance in type 2 diabetes mellitus patients
title_fullStr Cost-Effectiveness of drug compliance in type 2 diabetes mellitus patients
title_full_unstemmed Cost-Effectiveness of drug compliance in type 2 diabetes mellitus patients
title_sort Cost-Effectiveness of drug compliance in type 2 diabetes mellitus patients
dc.creator.none.fl_str_mv Maciel, Olga
Vera, Zully
Marin, Gustavo Horacio
Maidana, Mabel
Samaniego, Lourdes
Lugo, Gladys
Mastroianni, Patricia
author Maciel, Olga
author_facet Maciel, Olga
Vera, Zully
Marin, Gustavo Horacio
Maidana, Mabel
Samaniego, Lourdes
Lugo, Gladys
Mastroianni, Patricia
author_role author
author2 Vera, Zully
Marin, Gustavo Horacio
Maidana, Mabel
Samaniego, Lourdes
Lugo, Gladys
Mastroianni, Patricia
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Cost-effectiveness
Type 2 Diabetes
Adherence
Pharmacotherapy compliance
topic Cost-effectiveness
Type 2 Diabetes
Adherence
Pharmacotherapy compliance
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Type 2 diabetes mellitus affects 15% of the population around the world, causing health complications and increasing the treatment’s costs. Being a chronic outpatient treatment disease, patient compliance is higher importance to achieve therapeutic success. The present study measure the cost effectiveness of the compliance of this disease. An observational, cross-sectional, pharmaco-economic study was performed. A National program to stimulate treatment adherence was taken as intervention stage. Compliance was measure by Morisky-Green test and details of the events in each patient's health (medication, consultations, hospitalization and concomitant treatments) were used to determinate the direct costs for Ministry of Public Health. Effectiveness was measured by percentage of glycated hemoglobin (HbA1c). The sample obtained was 55 patients, which were grouped into 31 compliant and 24 non-compliant. The costeffectiveness of compliance was 466 US$ / compliant effective patient and 1,807 US$ / non-compliant effective patient. The cost-effectiveness of hypoglycemic drug therapy compliance is significantly lower (almost 4 times) than non-compliance. Type 2 Diabetes Mellitus patients that have no therapy adherence are not able to maintain protective levels of HbA1c. In addition, for the Ministry of Public Health, the lack of adherence requires more budget to accomplished the health goals.
Fil: Maciel, Olga. Universidad Nacional de Asunción; Paraguay
Fil: Vera, Zully. Universidad Nacional de Asunción; Paraguay
Fil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Departamento de Articulación de Ciencias Básicas y Clínicas; Argentina
Fil: Maidana, Mabel. Universidad Nacional de Asunción; Paraguay
Fil: Samaniego, Lourdes. Universidad Nacional de Asunción; Paraguay
Fil: Lugo, Gladys. Universidad Nacional de Asunción; Paraguay
Fil: Mastroianni, Patricia. Universidade Estadual Paulista Julio de Mesquita Filho; Brasil
description Type 2 diabetes mellitus affects 15% of the population around the world, causing health complications and increasing the treatment’s costs. Being a chronic outpatient treatment disease, patient compliance is higher importance to achieve therapeutic success. The present study measure the cost effectiveness of the compliance of this disease. An observational, cross-sectional, pharmaco-economic study was performed. A National program to stimulate treatment adherence was taken as intervention stage. Compliance was measure by Morisky-Green test and details of the events in each patient's health (medication, consultations, hospitalization and concomitant treatments) were used to determinate the direct costs for Ministry of Public Health. Effectiveness was measured by percentage of glycated hemoglobin (HbA1c). The sample obtained was 55 patients, which were grouped into 31 compliant and 24 non-compliant. The costeffectiveness of compliance was 466 US$ / compliant effective patient and 1,807 US$ / non-compliant effective patient. The cost-effectiveness of hypoglycemic drug therapy compliance is significantly lower (almost 4 times) than non-compliance. Type 2 Diabetes Mellitus patients that have no therapy adherence are not able to maintain protective levels of HbA1c. In addition, for the Ministry of Public Health, the lack of adherence requires more budget to accomplished the health goals.
publishDate 2018
dc.date.none.fl_str_mv 2018-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/84321
Maciel, Olga; Vera, Zully; Marin, Gustavo Horacio; Maidana, Mabel; Samaniego, Lourdes; et al.; Cost-Effectiveness of drug compliance in type 2 diabetes mellitus patients; B. M. Vrushabendra Swamy; Research Journal of Pharmaceutical, Biological and Chemical Sciences; 9; 5; 10-2018; 1824-1829
0975-8585
CONICET Digital
CONICET
url http://hdl.handle.net/11336/84321
identifier_str_mv Maciel, Olga; Vera, Zully; Marin, Gustavo Horacio; Maidana, Mabel; Samaniego, Lourdes; et al.; Cost-Effectiveness of drug compliance in type 2 diabetes mellitus patients; B. M. Vrushabendra Swamy; Research Journal of Pharmaceutical, Biological and Chemical Sciences; 9; 5; 10-2018; 1824-1829
0975-8585
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.rjpbcs.com/2018_9.5.html
info:eu-repo/semantics/altIdentifier/url/https://www.rjpbcs.com/pdf/2018_9(5)/[230].pdf
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv B. M. Vrushabendra Swamy
publisher.none.fl_str_mv B. M. Vrushabendra Swamy
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083338695081984
score 13.22299

Publicaciones similares